

Baillie Gifford Worldwide Discovery Fund

30 June 2024

About Baillie Gifford

Philosophy	Long-term investment horizon A growth bias Bottom-up portfolio construction High active share
Partnership	100% owned by 58 partners with average 20 years' service Ownership aligns our interests with those of our clients Enables us to take a thoughtful, long-term view in all that we do Stability, quality and consistency

Investment Proposition

The Worldwide Discovery Fund seeks out initially immature entrepreneurial companies from across the world. Importantly, it is the immaturity of the opportunity which is key, and not just 'smallness'. Companies typically have a market capitalisation of \$10bn or smaller at time of initial purchase and will often have pronounced levels of innovation and a differentiated strategy. Highly asymmetric investment opportunities such as these are, we believe, ideal for bottom-up analysis, and it is in this opportunity set that inefficiencies and valuation anomalies can be most pronounced.

Fund Facts

Fund Launch Date	06 September 2017
Fund Size	\$272.5m / €254.3m
Index	MSCI ACWI Small Cap Index
Active Share	99%
Current Annual Turnover	14%
Current number of stocks	61
Fund SFDR Classification	Article 8*
Stocks (guideline range)	50-75
Fiscal year end	30 September
Structure	Irish UCITS
Base currency	USD

*The Fund is subject to enhanced sustainability-related disclosures on the environmental and/or social characteristics that it promotes.

Key Decision Makers

Name	Years' Experience
Douglas Brodie*	23

*Partner

Awards and Ratings – As at 31 May 2024



Class B Acc in USD.
Overall rating among
536 EAA Fund Global
Small/Mid-Cap Equity
funds as at 31-MAY-
2024.



Total Return

Lipper Ratings for Total Return is supplied by Lipper, a Refinitiv Company. Copyright 2024 © Refinitiv. All rights reserved. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereto. Lipper rating based on representative shareclass.



Based on the Class B USD Acc share class.

Periodic performance

	1 Month*	3 Months*	YTD*	1 Year*	3 Years	5 Years	10 Years	Since inception
US dollar								
Class B USD Acc (%)	3.9	-2.1	-11.9	-10.0	-25.5	-4.5	N/A	2.4
Index (%)	-1.2	-1.4	2.5	11.2	-0.3	7.8	N/A	6.9
euro								
Class B EUR Acc (%)	5.3	-1.4	-9.0	-8.9	-22.8	-3.3	N/A	4.0
Index (%)	0.1	-0.7	5.7	13.2	3.1	9.1	N/A	8.6
Canadian dollar								
Class B CAD Acc (%)	4.3	-1.4	-8.9	-7.0	-23.0	N/A	N/A	-4.7
Index (%)	-0.8	-0.3	6.4	14.9	3.1	N/A	N/A	8.2
New Zealand dollar								
Class B NZD Acc (%)	4.9	-3.9	-8.4	-9.9	-21.9	N/A	N/A	-3.6
Index (%)	-0.3	-3.2	6.6	11.8	4.4	N/A	N/A	8.9
sterling								
Class B GBP Acc (%)	4.5	-2.4	-11.4	-10.2	-23.2	-4.4	N/A	-2.0
Class B GBP Inc (%)	4.5	-2.4	-11.4	-10.2	-23.2	N/A	N/A	-4.2
Index (%)	-0.4	-1.5	3.4	11.8	2.7	7.9	N/A	7.9

Inception date	
US dollar	
Class B USD Acc	06 September 2017
euro	
Class B EUR Acc	06 September 2017
Canadian dollar	
Class B CAD Acc	25 November 2019
New Zealand dollar	
Class B NZD Acc	13 November 2019
sterling	
Class B GBP Acc	01 August 2018
Class B GBP Inc	08 November 2019

Calendar year performance

	December 2019	December 2020	December 2021	December 2022	December 2023
US dollar					
Class B USD Acc (%)	35.9	80.4	-22.0	-42.0	5.2
Index (%)	25.2	16.8	16.5	-18.3	17.4
euro					
Class B EUR Acc (%)	38.5	64.8	-15.5	-38.4	1.5
Index (%)	27.5	7.2	25.4	-12.9	13.4
Canadian dollar					
Class B CAD Acc (%)	N/A	76.7	-22.2	-38.3	2.9
Index (%)	N/A	14.8	15.5	-12.3	14.3
New Zealand dollar					
Class B NZD Acc (%)	N/A	68.5	-17.7	-37.4	5.6
Index (%)	N/A	9.5	22.6	-11.5	17.3
sterling					
Class B GBP Acc (%)	32.1	74.0	-21.2	-34.9	-0.4
Class B GBP Inc (%)	N/A	74.0	-21.2	-34.9	-0.4
Index (%)	20.4	13.2	17.6	-8.0	10.8

Discrete performance

	30/06/19-30/06/20	30/06/20-30/06/21	30/06/21-30/06/22	30/06/22-30/06/23	30/06/23-30/06/24
US dollar					
Class B USD Acc (%)	31.0	46.4	-53.7	-0.6	-10.0
Index (%)	-5.1	54.7	-21.5	13.6	11.2
euro					
Class B EUR Acc (%)	33.0	38.1	-47.2	-4.2	-8.9
Index (%)	-3.8	46.5	-10.9	8.9	13.2
Canadian dollar					
Class B CAD Acc (%)	N/A	32.8	-51.8	2.1	-7.0
Index (%)	N/A	40.6	-18.2	16.5	14.9
New Zealand dollar					
Class B NZD Acc (%)	N/A	34.2	-48.1	1.9	-9.9
Index (%)	N/A	42.5	-11.7	15.3	11.8
sterling					
Class B GBP Acc (%)	35.8	29.8	-47.2	-4.3	-10.2
Class B GBP Inc (%)	N/A	29.8	-47.2	-4.3	-10.2
Index (%)	-2.3	38.3	-10.7	8.5	11.8

	30/06/14-30/06/15	30/06/15-30/06/16	30/06/16-30/06/17	30/06/17-30/06/18	30/06/18-30/06/19
US dollar					
Class B USD Acc (%)	N/A	N/A	N/A	N/A	8.7
Index (%)	N/A	N/A	N/A	N/A	-2.5
euro					
Class B EUR Acc (%)	N/A	N/A	N/A	N/A	11.2
Index (%)	N/A	N/A	N/A	N/A	-0.1

Source: Revolution, MSCI. As at 30 June 2024. Net of fees. 10am prices. Index: MSCI ACWI Small Cap Index, calculated using close to close. *Not annualised. Hedged share classes shown against the index in the base currency.

Baillie Gifford operates a single swinging price for the Fund and, therefore, may apply a dilution adjustment to the price to protect long-term investors from the costs associated with buying and selling underlying investments that result from other investors joining or leaving the Fund. This adjustment will affect relative performance, either positively or negatively.

Stock Level Attribution

Top and Bottom Ten Contributors to Relative Performance, Quarter to 30 June 2024

Top Ten Contributors

Asset Name	Contribution (%)
Alnylam Pharmaceuticals	4.6
Twist Bioscience Corp	0.9
Aerovironment	0.9
American Superconductor Corp	0.8
STAAR Surgical	0.7
Veeco Instruments	0.7
TransMedics Group	0.6
Peptidream	0.5
Sweetgreen	0.4
Hashicorp Inc	0.3

Bottom Ten Contributors

Asset Name	Contribution (%)
Exact Sciences	-1.6
Sprout Social	-1.1
Ocado	-1.1
Schrodinger	-0.9
Appian Corp	-0.6
Oxford Nanopore Technologies	-0.6
Blackline	-0.5
dLocal	-0.5
Chegg	-0.4
Progyny	-0.4

Source: Revolution, MSCI. Baillie Gifford Worldwide Discovery Fund relative to MSCI ACWI Small Cap Index.

Some stocks may only have been held for part of the period.

All attribution figures are calculated gross of fees, relative to the Index from stock level up, based on closing prices.

Attribution is shown relative to the index therefore not all stocks shown are held in the portfolio. See the List of Holdings section of this report for the stocks held.

Market environment

Small-cap equity markets have remained volatile during the quarter. Much attention remains focused on the possible commencement of US Federal Reserve interest rate cuts. In the meantime, return-seeking capital seems drawn to a small handful of themes: Artificial Intelligence (AI) infrastructure, Bitcoin, and anti-obesity drugs. This has led to strong price appreciation among a small handful of companies, significantly outstripping index returns leading to historical concentration levels in indices such as the S&P 500. This thinness of growth has tended to favour larger, mega-cap businesses, and we've seen large-cap indices again outperform small.

Looking ahead, there are reasons to be bullish on the prospects for small-cap performance. Valuations for the asset class continue to look attractive compared to long-term historical averages and relative to larger businesses. Additionally, while the timing of interest rate cuts remains uncertain, we should expect small-cap equities to respond favourably.

Performance

Over the quarter, holdings in Alnylam Pharmaceutical, AeroVironment, and American Superconductor (AMSC) were among the most significant positive contributors to fund relative performance. Alnylam, a clinical biotech developing a range of treatments based on a singular approach to gene silencing, is the fund's largest holding. Shares in the company rallied significantly on positive news from the phase three trial of its treatment for patients with ATTR amyloidosis with cardiomyopathy (a progressive and deadly form of heart disease). Alnylam plans to proceed with global regulatory submissions later this year. If approved, it is expected to generate between \$2-4bn in annual sales (a considerable increase on Alnylam's current \$1.5bn annual sales). We are delighted by the results, as it should unlock a significant commercial opportunity that will generate cash to facilitate the push of other assets through the pipeline (e.g., in Alzheimer's and hypertension). Shares in AeroVironment, the manufacturer of advanced drones primarily for military purposes, were also strong over the quarter. The company is experiencing heightened product demand, with the US Department of Defence placing several large orders. This has

resulted in rapid sales growth, expanding margins, and a burgeoning order backlog. The company have issued encouraging guidance for FY2025, suggesting between 10-15% top-line growth and decent profitability. Over the quarter, AMSC, a solutions provider for the wind and power industries, delivered pleasing results that offered surprises on both the top and bottom lines. Reported sales came in ahead of previously issued guidance and consensus expectations. The company highlighted diversifying demand across renewables, industrial and the US Navy as the driver for this. Simultaneously, the business reported positive non-GAAP EPS and operating cash flow when expectations had been for continued losses. While this is encouraging, we're excited about what's to come, with the company highlighting opportunities across data-centre development, modular power substations, and grid resilience.

Holdings in Exact Sciences, Sprout Social and Ocado were among the most prominent negative contributors to relative performance. Exact has developed a stool-based colorectal cancer test (Cologuard) and several other tests which inform the treatment of cancers. The market is concerned by several competitive threats facing Exact, with the US FDA recently approving Geneoscopy's colorectal cancer test and Guardant's blood screening test. Cologuard remains leading in its ability to detect earlier-stage cancers, but competing tests could take some share due to superior convenience. With Exact's ten years of experience in colorectal screening and its entrenched sales force, it has a more defensible lead than is appreciated. Sprout Social is a software business whose products help companies to manage their social media presence. Shares fell materially during the quarter due to disappointing results, which reveal ongoing sales execution challenges. Sprout has attempted to re-orientate the company to a high-value, enterprise customer segment. While this has reduced customer numbers, it was hoped that larger customers would more than offset any lost revenue. Thanks to a tie-up with Salesforce and a robust competitive position, the business was expected to gain momentum through the year. This has, however, yet to materialise, signified by a 5% reduction in full-year guidance and narrative around continued sales difficulties. This is highly disappointing, and we will keenly watch the upcoming results before

making any decisions regarding the position. Ocado, the UK grocer and international grocery fulfilment business, has had a challenging quarter. Shares traded lower on the news that one of its global partners, Sobeys in Canada, was pausing the rollout of further fulfilment centres and concluding its partnership. While disappointing, the deal with Sobeys was always less significant than that with Kroger in the US. Encouragingly, the Kroger CEO has spoken positively over the quarter about their partnership with Ocado and the planned collaboration for further growth.

Notable transactions

New buys: E-Ink, MP Materials, Raspberry Pi, Sweetgreen. Complete sales: Chegg, Fiverr, HashiCorp, M3, MonotaRo, StratasyS.

Transactions from 01 April 2024 to 30 June 2024.


New Purchases

Stock Name	Transaction Rationale
E Ink	E Ink is the category-defining e-paper maker. By digitising traditionally static surfaces, the company enables products like e-book readers, Electronic Shelf Labels (ESL), and broader Internet of Things uses. With an upstream monopoly over this technology, it's the current leader of a maturing ecosystem, and it is set to benefit as e-paper commercialises across numerous applications. While synonymous with e-books, we believe the recent Walmart ESL deal and an expanding pipeline of use cases, such as education tablets, are catalysing the product's growth inflection and improving E Ink's margin profile.
MP Materials	MP Materials owns and operates Mountain Pass, a mine in California with a uniquely high-quality reserve of rare earth metals, neodymium and praseodymium, which are key to manufacturing powerful and efficient magnets. Several burgeoning technologies, such as EVs, wind turbines, drones and robotics, are reliant on magnets and demand is poised to outstrip supply, most of which is currently sourced from China. MP's ambition is to evolve beyond a raw materials vendor to a magnet maker, and they have taken successful, albeit early, steps on that journey. We are excited by the prospects that the company might position itself as the only vertically integrated Western supplier of rare earth magnets critical for multiple secular growth industries.
Raspberry Pi	We have taken an initial position in Raspberry Pi, a British company that makes low-cost, compact single-board computers and computing modules. Originally designed to appeal to educators and hobbyists, these general-purpose computers have seen strong traction with a growing number of industrial customers for which they act as the "brains" in factories and end products. The company enjoys high organic awareness and a strong community of loyal users, which positions them front of mind among professional engineers. The depth and breadth of the software ecosystem around these computers, coupled with the company's investment in owning more of the hardware itself, have further strengthened its competitive moat. They remain early in monetising the opportunity with industrial customers. Still, the demand for Raspberry Pi computers and compute modules is expected to grow, underpinned by secular drivers like the Internet of Things and Edge Artificial Intelligence (AI).
Sweetgreen	We have taken a new holding in Sweetgreen for the Fund. Sweetgreen sells salads to a fast food model and is part of the structural consumer trend towards healthier eating. The company is early in its opportunity - they have a little over 200 stores in the US, with a long-run target of 1000+ stores in a decade. There are multiple levers management can pull for growth beyond store expansion: increased customer engagement, expanding channels, and driving store profitability through automation. It has positive store economics and plans to hold general and administrative costs flat while increasing store count, driving leverage and the company towards profitability. We are also encouraged by Sweetgreen's shift toward a suburban store mix alongside in-store automation, which brings stronger margins. The company has built up a strong network of local suppliers over the last decade, and we are impressed by the long-term mindset of the three founders who still run the business and the experienced team they have built around them to scale to the next level.

Complete Sales


Stock Name	Transaction Rationale
Chegg	We have sold the position in the education business, Chegg. The company supports learners at schools, colleges, and universities through its study resources, online tutoring, and learning tools. It has made a substantial shift online from its printed study guide heritage. Still, we have been disappointed by the company's progress when challenged first by the disruption to students caused by Covid and then by the emergence of artificial intelligence competition. From here, we have not been able to build investment conviction in the management team's strategy. Amidst underwhelming current financial progress, we decided to sell this position from the Fund.
Fiverr Intl	Fiverr is a global freelancing website principally catering to small businesses, offering them the ability to outsource digital tasks typically of low value (average ticket <\$200). Following several team debates around the impact of generative AI, we believe Fiverr's core business is on the wrong side of this disruption and that this has the potential to jeopardise its long-term growth prospects. We have, therefore, sold the position.
Hashicorp Inc	HashiCorp provides a suite of software tools designed to simplify and secure software management across customers' computing infrastructure. Computing conglomerate IBM announced in April that it would acquire HashiCorp. We have decided to sell the shares rather than wait for the acquisition to complete.
M3	M3 operates Japan's largest online drug advertising and marketing platform. Its primary service is delivering drug information to doctors. It also operates in adjacent areas, such as clinical trial services and specialist job search. The growth runway for the core medical portal business remains strong as more pharmaceutical companies shift their marketing budgets online. However, as the company diversifies into new geographies and services, and makes more significant acquisitions, the business is becoming more complex to manage, resulting in greater execution risk. This is compounded by poor transparency. Despite a de-rating in the shares, we have decided to sell the position.
MonotaRO Co	We have sold the shares in MonotaRO Co, a Japanese e-commerce company that sells industrial supply products. A long-standing position for the strategy, it remains a high-quality business, but ultimately, its growth has been slowing for the last few years. Following its release of uninspiring guidance for FY2024, we decided to take advantage of the resilient market rating to exit the position.
Stratasys	Stratasys manufactures three-dimensional (3D) printers and 3D-production systems. Our conviction in the company's ability to execute its vision of making 3D printing mainstream and disrupting manufacturing supply chains has decreased. This stems from what we see as self-imposed harm from poor integration of acquisitions and the associated negative impact on internal culture, which may prove to be irreversible. Additionally, the demand for additive manufacturing seems to have stalled, yet competition has increased. We have, therefore, decided to sell the holding.

Geographic Exposure



		%
1	United States	71.1
2	UK	8.6
3	Israel	4.8
4	Brazil	2.9
5	China	2.6
6	Japan	2.6
7	Denmark	2.1
8	Others	3.7
9	Cash	1.7

Sector Exposure



		%
1	Health Care	39.6
2	Information Technology	27.8
3	Industrials	14.7
4	Financials	4.3
5	Consumer Discretionary	4.3
6	Real Estate	3.9
7	Consumer Staples	2.0
8	Materials	0.9
9	Communication Services	0.8
10	Cash	1.7

Portfolio Characteristics

	Fund	Index
Market Cap (weighted average)	\$9.1bn	\$4.2bn
Price/Book	4.2	1.7
Price/Earnings (12 months forward)	32.3	13.7
Earnings Growth (5 year historic)	-16.0%	3.4%
Return on Equity	-3.6%	11.0%
Predicted Beta (12 months)	1.5	N/A
Standard Deviation (trailing 3 years)	27.3	18.3
R-Squared	0.9	N/A
Delivered Tracking Error (12 months)	14.4	N/A
Sharpe Ratio	-0.5	0.4
Information Ratio	-1.4	N/A
		Fund
Number of geographical locations		12
Number of sectors		9
Number of industries		24

Source: FactSet, MSCI.

We have provided these characteristics for information purposes only. In particular, we do not think index relative metrics are suitable measures of risk. Fund and benchmark figures are calculated excluding negative earnings.

As well as cash in the bank, the cash balance includes unsettled cash flows arising from both shareholder flows and outstanding trades. Therefore, a negative balance may arise from timing differences between shareholder flows and security trading and does not necessarily represent a bank overdraft.

Top Ten Holdings

	Holdings	% of Total Assets
1	Alnylam Pharmaceuticals	8.5
2	AeroVironment	5.0
3	Axon Enterprise	4.9
4	Zillow	3.9
5	STAAR Surgical	3.5
6	Twist Bioscience	2.7
7	CyberArk	2.7
8	MarketAxess	2.7
9	Veeco Instruments	2.7
10	Oxford Nanopore Tech	2.6

Voting Activity

Votes Cast in Favour		Votes Cast Against		Votes Abstained/Withheld	
Companies	45	Companies	18	Companies	5
Resolutions	456	Resolutions	21	Resolutions	6

Please consider all of the characteristics and objectives of the fund as described in the Key Information Document (KID) and prospectus before making a decision to invest in the Fund. For more information on how sustainability issues, such as climate change are considered, see bailliegifford.com.

Company Engagement

Engagement Type	Company
Environmental	Ambarella, Inc., Axon Enterprise, Inc., MP Materials Corp.
Social	Axon Enterprise, Inc.
Governance	Alnylam Pharmaceuticals, Inc., Ambarella, Inc., Axon Enterprise, Inc., Kingdee International Software Group Company Limited, PureTech Health plc, STAAR Surgical Company, Trupanion, Inc., Zai Lab Limited, Zillow Group, Inc.
Strategy	Ambarella, Inc., Kingdee International Software Group Company Limited, MercadoLibre, Inc.

Asset Name	Fund %	Asset Name	Fund %
Alnylam Pharmaceuticals	8.5	Genus	0.8
AeroVironment	5.0	E Ink	0.7
Axon Enterprise	4.9	Beam Therapeutics	0.7
Zillow	3.9	Cosmo Pharmaceuticals	0.7
STAAR Surgical	3.5	DLocal	0.6
Twist Bioscience	2.7	EverQuote	0.6
CyberArk	2.7	Codexis	0.6
MarketAxess	2.7	Infomart	0.6
Veeco Instruments	2.7	QuantumScape Corporation	0.4
Oxford Nanopore Tech	2.6	Adaptimmune Therapeutics	0.4
Exact Sciences	2.5	AbCellera Biologics	0.4
Schrödinger	2.4	Ceres Power	0.3
Appian	2.3	freee K.K	0.3
MercadoLibre	2.2	Raspberry Pi Foundation	0.3
JFrog	2.1	Cardlytics	0.2
Genmab	2.1	ITM Power	0.2
Upwork	2.0	Collectis	0.2
Ocado	2.0	Chinook Therapeutics	0.0
LiveRamp	1.9	Cash	1.7
American Superconductor Corp	1.8	Total	100.0
Zuora	1.8	Total may not sum due to rounding.	
Sprout Social	1.8	Please note the fund information contained within this document is proprietary information and should be maintained as such and not disseminated. The content is intended for information purposes only and should not be disclosed to other third parties or used for the purposes of market timing or seeking to gain an unfair advantage.	
Xero	1.7		
PeptiDream	1.7		
BlackLine	1.7		
Sweetgreen	1.6		
Kingdee International Software	1.5		
Progyny	1.4		
Novocure	1.3		
TransMedics Group	1.3		
Confluent	1.3		
Pacira BioSciences	1.3		
PureTech Health	1.2		
RxSight, Inc	1.2		
Doximity	1.1		
Ambarella	1.1		
Zai Lab	1.1		
Trupanion	1.0		
Renishaw	1.0		
Aehr Test Systems	1.0		
IPG Photonics	1.0		
Digimarc	1.0		
MP Materials	0.9		

	Inception date	ISIN	Bloomberg	SEDOL	WKN	Valoren	Ongoing charge figure (%)	Annual management fee (%)
euro								
Class A EUR Acc	12 April 2019	IE00BJ5JS224	BGWDAEA ID	BJ5JS22	A2PGZU	47480657	1.63	1.50
US dollar								
Class B USD Acc	06 September 2017	IE00BD09K416	BGDIBUA ID	BD09K41	A2QC33	38235136	0.88	0.75
euro								
Class B EUR Acc	06 September 2017	IE00BD09K309	BGDIBEA ID	BD09K30	A2PFCD	38235173	0.88	0.75
Canadian dollar								
Class B CAD Acc	25 November 2019	IE00BKLC2X16	BGDIFFA ID	BKLC2X1	A2PV4M	51299539	0.88	0.75
New Zealand dollar								
Class B NZD Acc	13 November 2019	IE00BK63G481	BGWDFNA ID	BK63G48	A2PVFY	51151267	0.88	0.75
sterling								
Class B GBP Acc	01 August 2018	IE00BG88PY66	BGDIFGA ID	BG88PY6	A2QC34	43084053	0.88	0.75
Class B GBP Inc	08 November 2019	IE00BJ7W3579	BGWDFGI ID	BJ7W357	A2PU9A	51047808	0.88	0.75

Our Worldwide funds allow us to offer multi-currency share classes. Share classes can be created on request. The ongoing charge figure is at the latest annual or interim period. Charges will reduce the value of your investment. Costs may increase or decrease as a result of currency and exchange rate fluctuations.

Risks and Additional Information

The Fund is a sub-fund of Baillie Gifford Worldwide Funds PLC which is an established umbrella fund. Its Investment Manager and Distributor is Baillie Gifford Investment Management (Europe) Limited ("BGE"). This document does not provide you with all the facts that you need to make an informed decision about investing in the Fund. Further details of the risks associated with investing in the Fund can be found in the Key Information Document (KID), or the Prospectus.

A Prospectus is available for Baillie Gifford Worldwide Funds plc (the Company) in English, French and German. Key Information Documents (KIDs) are available for each share class of each of the sub-funds of the Company and in one of the official languages of each of the EU Member States into which each sub-fund has been notified for marketing under the Directive 2009/65/EC (the UCITS Directive). These can be obtained from bailliegifford.com. In addition, a summary of investor rights is available from bailliegifford.com. The summary is available in English.

The sub-funds of the Company are currently notified for marketing into a number of EU Member States under the UCITS Directive. The Company can terminate such notifications for any share class and/or sub-fund of the Company at any time using the process contained in Article 93a of the UCITS Directive.

Nothing in the document should be construed as advice and it is therefore not a recommendation to buy or sell shares.

By investing in the Fund you own shares in the Fund. You do not have ownership or control of the underlying assets such as the stocks and shares of the companies that make up the portfolio as these are owned by the Fund.

The ongoing charges figure is based on actual expenses for the latest financial period. Where the share class has been launched during the financial period and / or expenses during the period are not representative, an estimate of expenses may have been used instead. It may vary from year to year. It excludes the costs of buying and selling assets for the Fund although custodian transaction costs are included. Where a share class has not been seeded an estimate of expenses has been used.

Please note that no annual performance figures will be shown for a share class that has less than a full 12 months of quarterly performance.

This document contains information on investments which does not constitute independent research. Accordingly, it is not subject to the protections afforded to independent research and Baillie Gifford and its staff may have dealt in the investments concerned. It is classified as advertising in Switzerland under Art 68 of the Financial Services Act ("FinSA").

This document is issued by Baillie Gifford Overseas Limited ("BGO") which provides investment management and advisory services to non-UK clients. BGO is wholly owned by Baillie Gifford & Co. Both are authorised and regulated in the UK by the Financial Conduct Authority. BGO is registered with the SEC in the United States of America, and is licensed with the Financial Sector Conduct Authority in South Africa as a Financial Services Provider. The Fund is authorised in Ireland and regulated by the Central Bank of Ireland.

BGE is authorised by the Central Bank of Ireland as an AIFM under the AIFM Regulations and as a UCITS management company under the UCITS Regulation. BGE also has regulatory permissions to perform Individual Portfolio Management activities. BGE provides investment management and advisory services to European (excluding UK) segregated clients. BGE has been appointed as UCITS management company to the following UCITS umbrella company; Baillie Gifford Worldwide Funds plc.

Baillie Gifford Asia (Hong Kong) Limited 柏基亞洲(香港)有限公司 ("BGA") holds a Type 1 licence from the Securities and Futures Commission of Hong Kong to market and distribute Baillie Gifford's range of collective investment schemes to professional investors in Hong Kong. Baillie Gifford International LLC was formed in Delaware in 2005 and is registered with the SEC. It is the legal entity through which BGO provides client service and marketing functions in North America.

Baillie Gifford International LLC, BGE and BGA are a wholly owned subsidiaries of Baillie Gifford Overseas Limited. All information is sourced from Baillie Gifford & Co. All amounts in share class currency and as at the date of the document unless otherwise stated. All figures are rounded, so any totals may not sum.

Investment markets can go down as well as up and market conditions can change rapidly. The value of an investment in the Fund, and any income from it, can fall as well as rise and investors may not get back the amount invested.

The specific risks associated with the Fund include:

Any value assigned to illiquid securities which are difficult to trade, such as those in smaller, immature companies, may not accurately reflect the price the Fund might receive upon their sale.

Custody of assets involves a risk of loss if a custodian becomes insolvent or breaches duties of care.

Investment in smaller, immature companies is generally considered higher risk as the market for their shares may be less liquid and more difficult to trade than that for more established companies. As a result, share price fluctuations may be greater. In addition, smaller, immature companies may not do so well in periods of adverse economic conditions. Where such companies have business models and competitive positions which are less well established, this could result in an increased likelihood of loss for investors.

The Fund's concentration in a particular geographical area or industry may result in large movements in the share price in the short term.

The Fund has exposure to foreign currencies and changes in the rates of exchange will cause the value of any investment, and income from it, to fall as well as rise and you may not get back the amount invested.

The Fund's approach to Environmental, Social and Governance (ESG) means it cannot invest in certain sectors and companies. The universe of available investments will be more limited than other funds that do not apply such criteria/ exclusions, therefore the Fund may have different returns than a fund which has no such restrictions. Data used to apply the criteria may be provided by third party sources and is based on backward-looking analysis and the subjective nature of non-financial criteria means a wide variety of outcomes are possible. There is a risk that data provided may not adequately address the underlying detail around material non-financial considerations.

Please consider all of the characteristics and objectives of the fund as described in the Key Information Document (KID) and prospectus before making a decision to invest in the Fund. For more information on how sustainability issues, such as climate change are considered, see bailliegifford.com.

The Fund's share price can be volatile due to movements in the prices of the underlying holdings and the basis on which the Fund is priced.

Further details of the risks associated with investing in the Fund can be found in the Key Information Document (KID), or the Prospectus. Copies of both the KID and Prospectus are available at bailliegifford.com.

Definitions

Active Share - A measure of the Fund's overlap with the benchmark. An active share of 100 indicates no overlap with the benchmark and an active share of zero indicates a portfolio that tracks the benchmark.

Awards and Ratings

The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance does not predict future returns.

Target Market

The Fund is suitable for all investors seeking a fund that aims to deliver capital growth over a long-term investment horizon by investing in companies focused on sustainable value creation. The Fund integrates the consideration of environmental, social and governance matters as part of the investment process through the use of qualitative analysis and quantitative screens. The investor should be prepared to bear losses. The Fund is compatible for mass market distribution. The Fund may not be suitable for investors who are concerned about short-term volatility and performance, seeking a regular source of income and investing for less than five years. The Fund does not offer capital protection.

Legal Notices

Source: MSCI. MSCI makes no express or implied warranties or representations and shall have no liability whatsoever with respect to any MSCI data contained herein. The MSCI data may not be further redistributed or used as a basis for other indexes or any securities or financial products. This report is not approved, endorsed, reviewed or produced by MSCI. None of the MSCI data is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such.

Financial Intermediaries

This document is suitable for use of financial intermediaries. Financial intermediaries are solely responsible for any further distribution and Baillie Gifford takes no responsibility for the reliance on this document by any other person who did not receive this document directly from Baillie Gifford.

Additional Geographical Location Information

Australia: Baillie Gifford Overseas Limited (ARBN 118 567 178) is registered as a foreign company under the Corporations Act 2001 (Cth) and holds Foreign Australian Financial Services Licence No 528911. This document is provided to you on the basis that you are a "wholesale client" within the meaning of section 761G of the Corporations Act 2001 (Cth) ("Corporations Act"). Please advise Baillie Gifford Overseas Limited immediately if you are not a wholesale client. In no circumstances may this document be made available to a "retail client" within the meaning of section 761G of the Corporations Act. This document contains general information only. It does not take into account any person's objectives, financial situation or needs.

Canada: BGO is not resident in Canada, its head office and principal place of business is in Edinburgh, Scotland. Baillie Gifford Overseas Limited is regulated in Canada as a portfolio manager and exempt market dealer with the Ontario Securities Commission ('OSC'). Its portfolio manager licence is currently passported into Alberta, Quebec, Saskatchewan, Manitoba and Newfoundland & Labrador whereas the exempt market dealer licence is passported across all Canadian provinces and territories. Baillie Gifford International LLC is regulated by the OSC as an exempt market and its licence is passported across all Canadian provinces and territories. Baillie Gifford Investment Management (Europe) Limited ('BGE') relies on the International Investment Fund Manager Exemption in the provinces of Ontario and Quebec.

Chile: In Chile (i) La presente oferta se acoge a la Norma de Carácter General N° 336 de la Comisión para el Mercado Financiero (CMF) de Chile.

(ii) La presente oferta versa sobre valores no inscritos en el Registro de Valores o en el Registro de Valores Extranjeros que lleva la Comisión para el Mercado Financiero, por lo que los valores sobre los cuales ésta versa, no están sujetos a su fiscalización;

(iii) Que por tratarse de valores no inscritos, no existe la obligación por parte del emisor de entregar en Chile información pública respecto de estos valores; y

(iv) Estos valores no podrán ser objeto de oferta pública mientras no sean inscritos en el Registro de Valores correspondiente.

(v) Este material no constituye una evaluación o recomendación para invertir en instrumentos financieros o proyectos de inversión.

Colombia: The securities have not been, and will not be, registered with the Colombian National Registry of Securities and Issuers (Registro Nacional de Valores y Emisores) or traded on the Colombian Stock Exchange (Bolsa de Valores de Colombia). Unless so registered, the securities may not be publicly offered in Colombia or traded on the Colombian Stock Exchange. The investor acknowledges that certain Colombian laws and regulations (including but not limited to foreign exchange and tax regulations) may apply in connection with the investment in the securities and represents that it is the sole liable party for full compliance therewith.

Denmark: The Danish Financial Supervisory Authority has received proper notification of the marketing of units or shares in the Fund to investors in Denmark in accordance with the Danish Investment Associations Act and the executive orders issued pursuant thereto.

Isle of Man: In the Isle of Man the Fund is not subject to any form of regulation or approval in the Isle of Man. This document has not been registered or approved for distribution in the Isle of Man and may only be distributed in or into the Isle of Man by a person permitted under Isle of Man law to do so and in accordance with the Isle of Man Collective Investment Schemes Act 2008 and regulations made thereunder. BGE is not regulated or licensed by the Isle of Man Financial Services Authority and does not carry on business in the Isle of Man.

Israel: This factsheet, as well as investment in the Fund described herein, is directed at and intended for Investors that fall within at least one category in each of: (1) the First Schedule of the Israeli Securities Law, 1968 ("Sophisticated Investors"); and (2) the First Schedule of the Investment Advice Law ("Qualified Clients").

Jersey: In Jersey consent under the Control of Borrowing (Jersey) Order 1958 (the "COBO Order") has not been obtained for the circulation of this document.

Mexico: In Mexico the Fund has not and will not be registered in the National Registry of Securities maintained by the National Banking and Securities Commission, and therefore may not be offered or sold publicly in Mexico. The Fund may be offered or sold to qualified and institutional investors in Mexico, pursuant to the private placement exemption set forth under Article 8 of the Securities Market Law as part of a private offer.

Peru: The Fund has not and will not be registered in the Public Registry of the Capital Market (Registro Público del Mercado de Valores) regulated by the Superintendency of the Capital Market (Superintendencia del Mercado de Valores - "SMV"). Therefore, neither this document, nor any other document related to the program has been submitted to or reviewed by the SMV. The Fund will be placed through a private offer aimed exclusively at institutional investors. Persons and/or entities that do not qualify as institutional investors should refrain from participating in the private offering of the Fund.

Singapore: In Singapore the Fund is on the Monetary Authority of Singapore's List of Restricted schemes. This document has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this information memorandum and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of shares in the Fund may not be circulated or distributed, nor may the shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i) to an institutional investor pursuant to Section 304 of the Securities and Futures Act, Chapter 289 of Singapore (the "SFA") or (ii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.

South Korea: In South Korea Baillie Gifford Overseas Limited is registered with the Financial Services Commission as a cross-border foreign Discretionary Investment Manager & Non-Discretionary Investment Adviser.

Spain: In Spain BAILLIE GIFFORD WORLDWIDE FUNDS PLC is registered with the Securities Market Commission under official registration number 1707.

Switzerland: In Switzerland this document is directed only at qualified investors (the "Qualified Investors"), as defined in the Swiss Collective Investment Schemes Act of 23 June 2006, as amended ("CISA") and its implementing ordinance. The Fund is a sub-fund of Baillie Gifford Worldwide Funds PLC and is domiciled in Ireland. The Swiss representative is UBS Fund Management (Switzerland) AG, Aescheneplatz 6, 4052 Basel. The Swiss paying agent is UBS Switzerland AG, Bahnhofstrasse 45, 8001 Zurich. The documents of the Company, such as the Partial Prospectus for Switzerland, the Articles of Association, the Key Information Documents (KIDs), and the financial reports can be obtained free of charge from the Swiss representative. For the shares of the Fund distributed to qualified investors in Switzerland, the place of jurisdiction is Basel. Each time performance data is published, it should be noted that the past performance is no indication of current or future performance, and that it does not take account of the commissions and costs incurred on the issue and redemption of shares.

Contact

Intermediary Enquiries

Email: funds@bailliegifford.com

Institutional Enquiries

Email: Institutional.Enquiries@bailliegifford.com

Calton Square, 1 Greenside Row, Edinburgh EH1 3AN
Telephone +44 (0) 131 275 2000 bailliegifford.com

Copyright © Baillie Gifford & Co 2024. All rights reserved.

Ref 111206: